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Abstract
Fetomaternal haemorrhage was studied after 68 consecutive fetal intravascular transfusions performed in 20 patients with Rh isoimmunisation. (e Fetoprotein concentration was assayed in maternal blood taken before, and immediately after each transfusion and three and 24 hours later. An increase of 50% or more in the concentration in any of the samples after transfusion was considered to indicate fetomaternal haemorrhage. Fetal a fetoprotein concentration in blood sampled before transfusion was also assayed and the amount of fetomatemal haemorrhage calculated. Fetomaternal haemorrhage occurred in 21 of 32 patients with an anterior placenta and in six of 36 with a posterior or fundal placenta. The mean estimated volume of haemorrhage was 2-4 ml, which was on average equal to 3 1% of the total fetoplacental blood volume. When the volume of fetomaternal haemorrhage at the first transfusion was greater than 1 ml there was a greater increase in maternal Rh (D) antibody titres and a greater fall in fetal packed cell volume. Sampling of fetal blood should not be routinely done early in patients with Rh isoimmunisation, and intrauterine transfusion should be delayed as long as possible. Sampling sites other than the placental cord insertion reduces the risk of fetomaternal haemorrhage.
Introduction
Intravascular blood transfusion has been advocated as the best approach to managing fetuses with severe Rh haemolytic disease. ' The aim of intravascular transfusion was to raise the fetal packed cell volume to about 0 4. The rate of infusion of donor blood (packed cell volume 06-08) was 1-7 ml/min. Throughout the procedure the fetal heart rate and the flow of transfused blood in the umbilical vein were monitored continuously by ultrasonography. In 46 procedures an intraperitoneal transfusion was carried out immediately after the intravascular transfusion. In all cases the whole procedure was accomplished within 45 minutes.
Maternal blood (2 ml) was taken before and immediately after the procedure and then three and 24 
Results
Fetomaternal haemorrhage occurred after 27 of the 68 intrauterine transfusions. The mean estimated volume of fetomaternal haemorrhage was 2-4 ml (confidence interval 1-5 to 3-7; range 0-3-15 4), which was on average equal to 3 1% of the total volume of fetoplacental blood (2-2 to 4-5; 0-5-14-0). A significant positive correlation (r=0-60, p<001) was found between the absolute volume of haemorrhage and gestational age, but no correlation was found between haemorrhage expressed as a percentage of the total volume of fetoplacental blood and gestational age.
An increase in maternal a fetoprotein concentration greater than 50% was found in 21 of the 32 patients with an anterior placenta and in six of the 36 with a posterior placenta; this difference was significant (p<0O001). When the site of sampling and transfusion was the placental cord insertion fetomaternal haemorrhage occurred in 18 patients with an anterior placenta and in five with a posterior placenta, whereas when it Table II relates the changes in maternal Rh (D) antibody concentrations to the volume of fetomaternal haemorrhage at the first transfusion. In those cases in which haemorrhage did not occur or was less than 1 ml the increase in Rh (D) concentration was always less than 150%, whereas five of the seven patients in whom haemorrhage was more than 1 ml had an increase of over 150%. In the two groups the median increase in antibody titre was 4% (range -15% to 127%) and 729% (-54% to 3206%) respectively; the difference was not significant. The rate of fall in fetal packed cell volume after the first transfusion was higher in those patients with a fetomaternal haemorrhage greater than 1 ml (mean 1-36%/day; confidence interval 0-93 to 1-78; range 0 7-2 0) than in those with haemorrhage of less than 1 ml (0-97%/day; 0-63 to 1-32; 0-5-1-4); the difference, however, was not significant.
Discussion
Transabdominal needling of the umbilical cord, especially if the cord insertion is on an anterior placenta, differs from other procedures as it seems to break the rule that penetration of the placenta should be avoided. Several reports have associated transplacental amniocentesis and fetoscopy with fetomaternal haemorrhage, and in fetoscopy intraamniotic bleeding from the placenta makes visualisation difficult and may lead to severe fetal anaemia. 14 
Administration ofanti-D immunoglobulin is routine after invasive procedures in Rh negative patients but is not appropriate for those already sensitised, in whom it would be ineffective. '5 In patients undergoing intrauterine transfusions, however, fetomaternal haemorrhage may enhance maternal sensitisation. Not only might the disease be worsened in a subsequent pregnancy but also in the present pregnancy the rate of fall in fetal packed cell volume might be accelerated by an increase in maternal antibody titre, particularly after the first transfusion, when fetal erythropoiesis is generally not yet suppressed.
Precisely estimating the volume of fetomaternal haemorrhage is difficult. In patients undergoing intrauterine transfusions the Kleihauer-Betke test cannot be used because donor red cells cannot be identified in the maternal circulation. The increase in maternal a fetoprotein concentration can give a reliable estimate if fetal a fetoprotein concentration is also assayed. Possible sources of error are the estimated maternal blood volume, which cannot practically be assessed in each patient, and passage of a fetoprotein into the maternal circulation from fluids other than fetal blood, such as the amniotic fluid. This second possibility is unlikely as fetomaternal haemorrhage occurred most commonly when the site of sampling and transfusion was the placental cord insertion with an anterior placenta-that is, when the needle entered directly into the cord without any communication with the amniotic cavity. Moreover, any contribution of a fetoprotein from the amniotic fluid to the rise in maternal a fetoprotein concentration should be irrelevant as the concentration in fetal blood is more than 100 times that in amniotic fluid. '6 De Silva et al reported that 0-28 ml of red cells produced a secondary Rh immune response in all of their 14 volunteers'7; in our study the increase in maternal Rh (D) antibody concentration was clinically important when the volume of haemorrhage was greater than 1 ml. As the mean fetal packed cell volume at the first transfusion was 0-20 (range 0-08-0-31) the results were comparable. In some instances the rise in antibody titre was dramatic, and although the consequences were not important as far as the rate of fall in fetal packed cell volume was concerned, the course of the disease in a subsequent pregnancy will probably be affected.
These results also suggest that sampling of fetal blood in patients with Rh isoimmunisation should not be routinely done for blood grouping early in pregnancy. To compare loudness the forks were presented alternately as air and bone conduction, and the patient was asked to report which was louder. In the comparison threshold method patients reported when they no longer heard the sound by bone conduction and were then asked whether they heard it again when it was presented by air. The responses were classified as Rinne positive if the sound by air conduction was louder than that by bone conduction, Rinne negative if bone conduction was louder than air conduction, and equivocal if the bone conduction and air conduction were equally loud. Subsequently, pure tone audiometric thresholds were assessed by standard methods. 2 We analysed the results from the better hearing ear (defined as better bone conduction at the frequency of the tuning fork used) to eliminate any potential need to
